Form 4: Royalty Pharma EVP & CFO Terrance P. Coyne Reports Acquisition of Class A Ordinary Shares

Terrance P. Coyne, EVP & CFO of Royalty Pharma plc, reports the acquisition of 48,646 Class A Ordinary Shares through the settlement of Equity Performance Awards.

Summary

• Terrance P. Coyne, the EVP & CFO of Royalty Pharma plc, filed a Form 4 on May 9, 2025, reporting a transaction that occurred on May 8, 2025.
• The transaction involved the acquisition of 48,646 Class A Ordinary Shares.
• These shares were acquired through the settlement of Equity Performance Awards, which is exempt under Rule 16b-3.
• Following the reported transaction, Coyne directly owns 1,500 Class A Ordinary Shares.
• Coyne also indirectly owns 48,646 Class A Ordinary Shares through TPC RP EPA1 LLC, 790,000 through TPC RP 2021, LLC, 23,270 through an IRA, 24,170 through a Spouse's IRA and 1,450 through a Spouse.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a routine disclosure of share acquisition through equity compensation.

Positives

• The acquisition of shares by a company executive can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are a routine part of compliance for company insiders and provide transparency into their transactions in the company's stock.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment due to the executive's increased stake in the company.

Key Dates

Keywords

Form 4, Royalty Pharma, RPRX, Terrance P. Coyne, Equity Performance Awards, Class A Ordinary Shares, Beneficial Ownership, EVP & CFO